The Challenge of Pulmonary Nontuberculous Mycobacterial Infection
- PMID: 26877911
- PMCID: PMC4749270
- DOI: 10.1007/s13665-015-0119-3
The Challenge of Pulmonary Nontuberculous Mycobacterial Infection
Abstract
The incidence of nontuberculous mycobacterial (NTM) lung disease is increasing. Current treatment strategies are largely based on expert opinion. The lack of randomized clinical trials to inform treatment leave clinicians with many questions regarding the most effective and safe regimens. The risk-benefit ratio of therapy is often thought to favor observation given the chronic nature of the disease, multiple long-term antibiotics recommended for therapy, side effects associated with treatment, and perceived lack of efficacious therapies.
Keywords: MAC; Mycobacterium abscessus; antibiotic resistance; nontuberculous mycobacterial (NTM) pulmonary disease; surgical therapy.
Figures
References
-
- Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med. 2007 Feb 15;175(4):367–416. - PubMed
-
- Falkinham JO., 3rd. Surrounded by mycobacteria: nontuberculous mycobacteria in the human environment. J Appl Microbiol. 2009 Aug;107(2):356–67. - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources